GENZYME
Updated 19 days ago
If ENJAYMO treatment is administered to patients with active systemic infections, monitor closely for signs and symptoms of worsening infection. Some infections may become rapidly life-threatening or fatal if not recognized and treated promptly. Inform patients of these signs and symptoms and steps to be taken to seek immediate medical care...
ENJAYMO is a breakthrough in Cold Agglutinin Disease (CAD)
Also known as: Genzyme Corporation
Associated domains: understandingcoldagglutinindisease.com